Companies Cryptocurrencies
Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc
Exchange: NasdaqGS
IPO Date: 18/03/2019
CEO: Dr. Peter M. Hecht
Biotechnology Healthcare 🔗
  • CYCN
  • 2.6401
  • 114254816
    market cap
  • -0.07990003
If you bought

shares of Cyclerion Therapeutics Inc (CYCN) on
You would have made
Old Price $12 Current Price $12

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. The company is headquartered in Cambridge, Massachusetts and currently employs 140 full-time employees. The firm is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The firm develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.

Address: 301 Binney St Boston MASSACHUSETTS 02142

Stay updated.